Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
35
ARTL Quote, Financials, Valuation and Earnings
Last price:
$1.91
Seasonality move
:
12.6%
Day range:
$1.84 - $1.94
52-week range:
$1.52 - $28.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.94x
Volume:
81.3K
Avg. volume:
1.2M
1-year change:
-70.61%
Market cap:
$1.4M
Revenue:
--
EPS (TTM):
-$17.30
Analysts' Opinion
-
Consensus RatingArtelo Biosciences, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.00, Artelo Biosciences, Inc. has an estimated upside of 827.84% from its current price of $1.94.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $1.94.
Fair Value
-
According to the consensus of 1 analyst, Artelo Biosciences, Inc. has 827.84% upside to fair value with a price target of $18.00 per share.
ARTL vs. S&P 500
-
Over the past 5 trading days, Artelo Biosciences, Inc. has underperformed the S&P 500 by -6.05% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Artelo Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Artelo Biosciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Artelo Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Artelo Biosciences, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Artelo Biosciences, Inc. reported earnings per share of -$3.96.
Enterprise value:
592.8K
EV / Invested capital:
1.85x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-260.52%
Net Income Margin (TTM):
--
Return On Equity:
-797.54%
Return On Invested Capital:
-626.18%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$10.2M | -$9.5M | -$12.4M | -$1.2M | -$3.1M | |
| EBITDA | -$10.2M | -$9.5M | -$12.4M | -$1.2M | -$3.1M | |
| Diluted EPS | -$3.32 | -$2.84 | -$17.30 | -$0.35 | -$3.96 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $20.2M | $13.4M | $5M | $1.8M | |
| Total Assets | -- | $22.4M | $15.5M | $7.1M | $4.3M | |
| Current Liabilities | -- | $480K | $921K | $697K | $4.9M | |
| Total Liabilities | -- | $512K | $921K | $775K | $4.9M | |
| Total Equity | -- | $21.9M | $14.6M | $6.4M | -$633K | |
| Total Debt | -- | $32K | -- | $78K | $40K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8M | -$8.4M | -$8.3M | -$858.4K | -$3.7M | |
| Cash From Investing | $2.5M | $10.1M | $54.8K | $4.3M | -$261.5K | |
| Cash From Financing | $664.9K | $81K | $5.6M | $800 | $3.6M | |
| Free Cash Flow | -$8M | -$8.4M | -$8.5M | -$858.4K | -$3.9M | |
ARTL
Sector
Market Cap
$1.4M
$28.7M
Price % of 52-Week High
6.78%
51.38%
Dividend Yield
0%
0%
Shareholder Yield
-154.06%
-1.4%
1-Year Price Total Return
-70.61%
-21.4%
Beta (5-Year)
1.063
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.86
200-day SMA
Sell
Level
$6.58
Bollinger Bands (100)
Sell
Level
2.04 - 9.04
Chaikin Money Flow
Sell
Level
-52.2M
20-day SMA
Buy
Level
$1.81
Relative Strength Index (RSI14)
Sell
Level
43.48
ADX Line
Sell
Level
35.94
Williams %R
Neutral
Level
-22.2469
50-day SMA
Sell
Level
$2.80
MACD (12, 26)
Sell
Level
-0.25
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
33.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-20.6636)
Sell
CA Score
(Annual)
Level (-4.1177)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (14.37)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
Stock Forecast FAQ
In the current month, ARTL has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ARTL average analyst price target in the past 3 months is $18.00.
-
Where Will Artelo Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Artelo Biosciences, Inc. share price will rise to $18.00 per share over the next 12 months.
-
What Do Analysts Say About Artelo Biosciences, Inc.?
Analysts are divided on their view about Artelo Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Artelo Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is Artelo Biosciences, Inc.'s Price Target?
The price target for Artelo Biosciences, Inc. over the next 1-year time period is forecast to be $18.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ARTL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Artelo Biosciences, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of ARTL?
You can purchase shares of Artelo Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Artelo Biosciences, Inc. shares.
-
What Is The Artelo Biosciences, Inc. Share Price Today?
Artelo Biosciences, Inc. was last trading at $1.91 per share. This represents the most recent stock quote for Artelo Biosciences, Inc.. Yesterday, Artelo Biosciences, Inc. closed at $1.94 per share.
-
How To Buy Artelo Biosciences, Inc. Stock Online?
In order to purchase Artelo Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ARTL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ARTL
Sector
P/E ratio
--
23.97x
PEG ratio
0.00x
-0.01x
P/B ratio
10.94x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
ARTL
Sector
Revenue growth
--
4.8%
Earnings growth
-1030.43%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.82
-$0.20
Profitability
ARTL
Sector
Profitability FY 2024
--
$3.5M
Return on invested capital
-626.18%
-31.16%
Return on assets
-260.52%
-27.72%
Return on equity
-797.54%
-37.13%
Earnings Date
Last Earnings Date
Mar
18
Next Earnings Date
Dec
12
Estimated Next Earnings Date
Mar
13
Balance Sheet
ARTL
Sector
Total cash
$1.7M
$27.2M
Short term investments
--
$26M
Total assets
$4.7M
$79.7M
Long term debt
$40K
$3.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
61
PLAB alert for Dec 11
Photronics, Inc. [PLAB] is up 6.18% over the past day.
Buy
77
DHIL alert for Dec 12
Diamond Hill Investment Group, Inc. [DHIL] is up 44.46% over the past day.
Buy
100
WRBY alert for Dec 11
Warby Parker, Inc. [WRBY] is up 2.23% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
